Panel on Health Services

List of follow-up actions
(Position as at 20 April 2017)

Subject	Date of meeting	Follow-up action required	Administration's response
1. Drug management of the Hospital Authority ("HA")	19 December 2016	The Administration/HA was requested to provide information on: (a) the progress of HA's liaison with the manufacturer on the arrangement to provide Eculizumab for patients with paroxysmal nocturnal haemoglobinuria; (b) the details on how individual public hospitals and clinics would formulate their local drug formularies according to the clinical needs of their patients; and (c) the differences in the local drug formularies of different public hospitals and clinics for treating patients with some common chronic diseases such as diabetes mellitus and hypertension.	The Administration will provide a response in due course.
2. Consultation Report on Voluntary Health Insurance Scheme ("VHIS")	16 January 2017	The Administration was requested to provide information on: (a) a breakdown of the use of the $50 billion earmarked for healthcare	The Administration will provide a response in due course.

Subject	Date of meeting	Follow-up action required	Administration's response
		reform. It was understood that $10 billion of which has been used for setting up the Hospital Authority Public-Private Partnership Fund, and part of which might be used for injecting funds into the High Risk Pool if, after the re-examination of the relevant proposal, it would be established under VHIS in the future; and (b) a breakdown of the expenditure involved on programmes aimed at helping to relieve the pressure on the public healthcare system, such as public-private partnership, and promotion of preventive care and primary care in order to reduce hospital admissions.	
3. Review of the fees and charges for public hospital services	16 January 2017	The Administration/HA was requested to provide information on: (a) the number of cases granted with medical fee waivers in the past three years, with a breakdown by whether or not the patients were recipients of Comprehensive Social Security	The Administration's response was issued to members vide LC Paper No. CB(2)1157/16-17(01) on 7 April 2017.

Subject	Date of meeting	Follow-up action required	Administration's response
		Assistance and the hospital services they received; (b) the timetable for the provision of public general outpatient services in the evening and/or during public holidays in each hospital cluster; and (c) the effectiveness of the introduction of the new charge for the Accident and Emergency services of HA in 2002 in continuously reducing the number of attendances, in particular the number of semi-urgent and non-urgent cases.	
4. Proposed regulatory framework for medical devices	16 January 2017	The Administration was requested to explain, in the form of a consolidated table, the classification of general medical devices under the proposed regulatory framework according to the recommended classification scheme of the International Medical Device Regulators Forum, as well as the use control categories recommended by the consultant commissioned by the Government to study the control of use of selected medical devices for cosmetic purposes.	The Administration will provide a response in due course.

Subject	Date of meeting	Follow-up action required	Administration's response
5. Briefing by the Secretary for Food and Health on the Chief Executive's 2017 Policy Address	26 January 2017	The Administration was requested to provide information on: (a) the increase in public health expenditure in the light of a growing number of elders aged 65 or above under an ageing population; and (b) programmes to promote preventive care for middle-aged adults in primary care setting and the expenditure involved.	The Administration will provide a response in due course.
6. Legislative proposal for conferring power on the Director of Health to issue recall order under the Chinese Medicine Ordinance (Cap. 549)	28 February 2017	The Administration was requested to provide information on the number of samples of Chinese herbal medicines drawn from the market for testing of pesticide residues (including organochlorine pesticide residues) and heavy metals contents; and the proportion of these numbers to the total number of Chinese herbal medicines sold in Hong Kong.	The Administration will provide a response in due course.
7. Legislative proposals for regulation of private healthcare facilities	28 February 2017	The Administration was requested to provide in the Legislative Council brief on the Private Healthcare Facilities Bill information on the respective numbers of day procedure centres performing the high-risk medical procedures set out in Annex A to LC Paper No. CB(2)845/16-17(01), and private clinics	The Administration will provide a response in due course.

Subject	Date of meeting	Follow-up action required	Administration's response
		which involved only solo practice or operated by not more than three/four/five registered medical practitioners or registered dentists; and their respective percentages to all day procedure centres and private clinics in the territory.	
8. Hong Kong Code of Marketing of Formula Milk and Related Products, and Food Products for Infants & Young Children ("the Hong Kong Code")	20 March 2017	The Administration was requested to provide information on: (a) the exclusive breastfeeding rate for infants at four months of age for babies born in 2016 as revealed by the biennial breastfeeding survey conducted by the Department of Health; and (b) the annual volume and value of powdered formula for infants and young children aged 36 months or below imported into Hong Kong.	The Administration will provide a response in due course.
	10 April 2017	The Administration was requested to provide information on: (a) a list of the countries that imposed restrictions on marketing practices of formula milk for infants and young children aged 36 months or below as	The Administration will provide a response in due course.

Subject	Date of meeting	Follow-up action required	Administration's response
		recommended in the International Code of Marketing of Breastmilk Substitutes developed by the World Health Organization and in subsequent relevant resolutions passed by the World Health Assembly; (b) whether it had consulted the Business Facilitation Advisory Committee and the Competition Commission on the Hong Kong Code and, if so, its response to the views and concerns, if any, raised by the two parties; (c) the number of prosecutions instituted under the Trade Descriptions Ordinance (Cap. 362) in the past three years against false or misleading nutrition and health claims on formula products for infants and children aged 36 months or below; and (d) the amount of funding provided to non-governmental organizations for the provision of guidance and support for breastfeeding mothers, and the number of organizations so involved.	

Subject	Date of meeting	Follow-up action required	Administration's response
9. Policy on and drugs for rare diseases	11 April 2017	The Administration/HA was requested to provide information on: (a) the amount of resources allocated by the Government to HA in the past two years for provision of drugs for treatment of rare diseases or uncommon disorders based on the examination of the relevant independent expert panels; and (b) the annual drug expenditure of HA for treatment of patients with rare diseases or uncommon disorders and the number of patients involved.	The Administration will provide a response in due course.

Council Business Division 2
Legislative Council Secretariat
21 April 2017